The Top 10 Dow Dividend Stocks for June

With so much uncertainty out there, investors could do a lot worse than buying into these venerable blue chips -- especially the reigning king of big payouts. More 

2 Stocks to Buy, 2 to Sell in Big Pharma

Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries. More 

Did Facebook Kill the Blockbuster IPO?

Social deals are all but dead, and overall IPO size just hasn't been the same. More 

Should I Buy Pfizer? 3 Pros, 3 Cons

Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More 

Q1 in Review: The Top 3 IPO Trends

The first quarter's in the books and turned out to be a solid one for IPOs. Let's take a look at the three sectors that kicked off 2013 the strongest. More 

3 Dow Jones Stocks to Buy

Investors would be wise to care less about the Dow Jones and more about its individual components -- namely, these three attractive blue chips. More 

Bausch & Lomb Prepping to Go Public?

A report says private equity investor Warburg Pincus is interviewing investment banks about a potential Bausch & Lomb IPO. More